Biotech firm creates weight loss pill that mimics the effects of gastric bypass surgery

Serving tech enthusiasts for over 25 years.TechSpot means tech analysis and advice you can trust Forward-looking: The rising popularity of GLP-1 receptor agonists like Ozempic and Wegovy has transformed obesity treatment and spurred competition among pharmaceutical companies to develop more effective alternatives. One such contender is Syntis Bio, a Boston-based biotech firm working on an oral medication designed to replicate the effects of gastric bypass surgery without the need for invasive procedures. The company recently unveiled promising early data at the European Congress on Obesity and Weight Management in Barcelona, highlighting the potential of its lead candidate, SYNT-101. SYNT-101 offers a novel approach to weight loss by temporarily altering nutrient absorption in the small intestine. Unlike GLP-1 drugs, which are administered via injection and often come with side effects such as nausea and vomiting, SYNT-101 is a once-daily pill that mimics the metabolic effects of gas ... Read full article.